

BÖLÜM 3

KEMİRGENLERDE DENEYSEL SEPSİS MODELLERİ

Murat ÇAKIR¹

1. GİRİŞ

Sepsis, enfeksiyonun tetiklediği düzensiz konak yanıtı sonucu ortaya çıkan, organ disfonksiyonu ile seyreden ve yüksek mortaliteye neden olan kompleks bir sendromdur. Dünya Sağlık Örgütü ve Sepsis-3 konsensusu, sepsisi enfeksiyona bağlı organ disfonksiyonu olarak tanımlamaktadır (1). Küresel ölçekte, sepsis yılda yaklaşık 48,9 milyon vakayı ve 11 milyona yakın ölümü beraberinde getirmektedir. Bu rakamlar, toplam küresel ölümlerin yaklaşık beşte birine denk gelmektedir (2).

Klinikte sepsis, oldukça heterojen bir tablo sergiler. Hastaların yaşları, komorbiditeleri, enfeksiyonun kaynağı, kullanılan antibiyotikler ve yoğun bakım koşulları sepsisin seyrini belirgin şekilde etkiler. Dolayısıyla insan sepsisinde gözlemlenen heterojenite, deneysel çalışmaların tasarımı da doğrudan zorlaştırmaktadır. Bu bağlamda, hayvan modelleri, sepsisin temel mekanizmalarının anlaşılması, immün yanıtın farklı evrelerinin araştırılması ve yeni tedavi stratejilerinin preklinik düzeyde test edilmesi için vazgeçilmez araçlardır (3). Kemirgenler (özellikle fare ve sıçan), sepsis çalışmalarında yaygın olarak kullanılan deney hayvanlarıdır. Bunun başlıca nedenleri arasında genetik homojenite, ucuz maliyet, hızlı üreme döngüsü, immün sistem hakkında kapsamlı bilgi birikimi ve deneysel protokollere kolay adaptasyonları yer almaktadır. Ayrıca transgenik ve knockout farelerin geliştirilmesi, belirli genlerin ve sinyal yollarının sepsis patofizyolojisindeki rollerinin incelenmesini mümkün kılmıştır (4).

Bu kitap bölümünde, kemirgenlerde kullanılan deneysel sepsis modelleri detaylı şekilde ele alınacak, avantaj ve dezavantajları tartışılacak, ayrıca gelecekteki perspektifler değerlendirilecektir.

¹ Doç. Dr., Yozgat Bozok Üniversitesi, Tıp Fakültesi, Fizyoloji AD.,
murat.cakir@yobu.edu.tr, ORCID iD: 0000-0002-2066-829X

KAYNAKLAR

1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*. 2016;315(8):801-10.
2. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. *Lancet*. 2020;395(10219):200-11.
3. Fink MP. Animal models of sepsis. *Virulence*. 2014;5(1):143-53.
4. Bertani B, Ruiz N. Function and Biogenesis of Lipopolysaccharides. *EcoSal Plus*. 2018;8(1).
5. Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. *Semin Immunopathol*. 2017;39(5):517-28.
6. Rubio I, Osuchowski MF, Shankar-Hari M, Skirecki T, Winkler MS, Lachmann G, et al. Current gaps in sepsis immunology: new opportunities for translational research. *Lancet Infect Dis*. 2019;19(12):e422-e36.
7. Jarczak D, Kluge S, Nierhaus A. Sepsis-Pathophysiology and Therapeutic Concepts. *Front Med (Lausanne)*. 2021;8:628302.
8. Tamayo E, Fernández A, Almansa R, Carrasco E, Heredia M, Lajo C, et al. Pro- and anti-inflammatory responses are regulated simultaneously from the first moments of septic shock. *Eur Cytokine Netw*. 2011;22(2):82-7.
9. Nierhaus A, Klatte S, Linssen J, Eismann NM, Wichmann D, Hedke J, et al. Revisiting the white blood cell count: immature granulocytes count as a diagnostic marker to discriminate between SIRS and sepsis--a prospective, observational study. *BMC Immunol*. 2013;14:8.
10. Poli-de-Figueiredo LF, Garrido AG, Nakagawa N, Sannomiya P. Experimental models of sepsis and their clinical relevance. *Shock*. 2008;30(7):53-9.
11. Cai L, Rodgers E, Schoenmann N, Raju RP. Advances in Rodent Experimental Models of Sepsis. *Int J Mol Sci*. 2023;24(11).
12. Morrison DC, Ryan JL. Endotoxins and disease mechanisms. *Annu Rev Med*. 1987;38:417-32.
13. Remick DG, Ward PA. Evaluation of endotoxin models for the study of sepsis. *Shock*. 2005;24 Suppl 1:7-11.
14. van der Poll T. Preclinical sepsis models. *Surg Infect (Larchmt)*. 2012;13(5):287-92.
15. Stortz JA, Raymond SL, Mira JC, Moldawer LL, Mohr AM, Efron PA. Murine models of sepsis and trauma: can we bridge the gap? *ILAR journal*. 2017;58(1):90-105.
16. Zhang S, Rahman M, Herwald H, Thorlacius H. Streptococcal M1 protein-induced lung injury is independent of platelets in mice. *Shock*. 2011;35(1):86-91.
17. Björck V, Pählman LI, Törnebrant J, Bodelsson M. Streptococcal M1 protein induces hyporesponsiveness and cytokine release from human arteries in a fibrinogen-dependent manner: a translational study. *Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine*. 2018;26(1):61.
18. Rao TS, Currie JL, Shaffer AF, Isakson PC. In vivo characterization of zymosan-induced mouse peritoneal inflammation. *The Journal of pharmacology and experimental therapeutics*. 1994;269(3):917-25.
19. Volman TJ, Hendriks T, Goris RJA. Zymosan-induced generalized inflammation: experimental studies into mechanisms leading to multiple organ dysfunction syndrome. *Shock*. 2005;23(4):291-7.
20. Wichterman KA, Baue AE, Chaudry IH. Sepsis and septic shock—a review of laboratory models and a proposal. *Journal of Surgical Research*. 1980;29(2):189-201.
21. Ayala A, Song GY, Chung CS, Redmond KM, Chaudry IH. Immune depression in polymicrobial sepsis: the role of necrotic (injured) tissue and endotoxin. *Crit Care Med*. 2000;28(8):2949-55.
22. Rittirsch D, Huber-Lang MS, Flierl MA, Ward PA. Immunodesign of experimental sepsis by cecal ligation and puncture. *Nat Protoc*. 2009;4(1):31-6.

23. Zantl N, Uebe A, Neumann B, Wagner H, Siewert JR, Holzmann B, et al. Essential role of gamma interferon in survival of colon ascendens stent peritonitis, a novel murine model of abdominal sepsis. *Infect Immun*. 1998;66(5):2300-9.
24. Maier S, Traeger T, Entleutner M, Westerholt A, Kleist B, Hüser N, et al. Cecal ligation and puncture versus colon ascendens stent peritonitis: two distinct animal models for polymicrobial sepsis. *Shock*. 2004;21(6):505-11.
25. Starr ME, Steele AM, Saito M, Hacker BJ, Evers BM, Saito H. A new cecal slurry preparation protocol with improved long-term reproducibility for animal models of sepsis. *PloS one*. 2014;9(12):e115705.
26. Wynn JL, Scumpia PO, Delano MJ, O'Malley KA, Ungaro R, Abouhamze A, et al. Increased mortality and altered immunity in neonatal sepsis produced by generalized peritonitis. *Shock*. 2007;28(6):675-83.
27. Doi K, Leelahavanichkul A, Yuen PS, Star RA. Animal models of sepsis and sepsis-induced kidney injury. *J Clin Invest*. 2009;119(10):2868-78.
28. Buras JA, Holzmann B, Sitkovsky M. Animal models of sepsis: setting the stage. *Nat Rev Drug Discov*. 2005;4(10):854-65.
29. Deitch EA. Animal models of sepsis and shock: a review and lessons learned. *Shock*. 1998;9(1):1-11.
30. Chen P, Stanojcic M, Jeschke MG. Differences between murine and human sepsis. *Surgical Clinics*. 2014;94(6):1135-49.
31. Assinger A, Schrottmaier WC, Salzmann M, Rayes J. Platelets in Sepsis: An Update on Experimental Models and Clinical Data. *Front Immunol*. 2019;10:1687.
32. Parker SJ, Watkins PE. Experimental models of gram-negative sepsis. *Br J Surg*. 2001;88(1):22-30.
33. Gow NAR, Yadav B. Microbe Profile: *Candida albicans*: a shape-changing, opportunistic pathogenic fungus of humans. *Microbiology (Reading)*. 2017;163(8):1145-7.
34. Kullberg BJ, Arendrup MC. Invasive candidiasis. *New England Journal of Medicine*. 2015;373(15):1445-56.
35. Sellers R, Clifford C, Treuting P, Brayton C. Immunological variation between inbred laboratory mouse strains: points to consider in phenotyping genetically immunomodified mice. *Veterinary pathology*. 2012;49(1):32-43.
36. Carreras E, Velasco de Andrés M, Orta-Mascaró M, Simões IT, Català C, Zaragoza O, et al. Discordant susceptibility of inbred C57BL/6 versus outbred CD1 mice to experimental fungal sepsis. *Cell Microbiol*. 2019;21(5):e12995.
37. Engoren M, Jewell ES, Douville N, Moser S, Maile MD, Bauer ME. Genetic variants associated with sepsis. *PLoS One*. 2022;17(3):e0265052.
38. Rosier F, Nuñez NF, Torres M, Liorid B, Rihet P, Pradel LC. Transcriptional response in a sepsis mouse model reflects transcriptional response in sepsis patients. *International Journal of Molecular Sciences*. 2022;23(2):821.
39. Beura LK, Hamilton SE, Bi K, Schenkel JM, Odumade OA, Casey KA, et al. Normalizing the environment recapitulates adult human immune traits in laboratory mice. *Nature*. 2016;532(7600):512-6.
40. Hamilton SE, Badovinac VP, Beura LK, Pierson M, Jameson SC, Masopust D, et al. New insights into the immune system using dirty mice. *The Journal of Immunology*. 2020;205(1):3-11.
41. Ito R, Takahashi T, Katano I, Ito M. Current advances in humanized mouse models. *Cellular & molecular immunology*. 2012;9(3):208-14.
42. Berton RR, Jensen IJ, Harty JT, Griffith TS, Badovinac VP. Inflammation Controls Susceptibility of Immune-Experienced Mice to Sepsis. *Immunohorizons*. 2022;6(7):528-42.